Primary Care Clinics in Waconia, MN Accepting Medicare
5 Primary Care Clinics found. Showing 1 - 5
 Lakeview Clinic, Ltd. Clinic/Center - Multi-Specialty Medicare: Medicare Enrolled Practice Location: 424 W State Highway 5, Waconia, MN 55387 Phone: 952-442-4461 Fax: 952-442-1547 |
Ridgeview Specialty Clinic Internal Medicine - Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 560 South Maple Street, Suite 220, Waconia, MN 55387 Phone: 952-442-8011 |
Odom Health And Wellness Family Medicine - Sports Medicine Medicare: Not Enrolled in Medicare Practice Location: 500 S Cherry St, Waconia, MN 55387 Phone: 952-856-4722 |
Ridgeview Clinics Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 500 S Maple St, Waconia, MN 55387 Phone: 952-442-2191 Fax: 952-442-8052 |
Minneapolis Heart Institute At Ridgeview Heart Center, Llc Internal Medicine Medicare: Medicare Enrolled Practice Location: 500 S Maple St, Waconia, MN 55387 Phone: 952-442-7843 |
News Archive
Congressman's visit to The American Legion beneficial to veterans
During a recent visit to The American Legion headquarters here, U.S. Rep. Bob Filner, D-Calif., said that the maintenance of high quality health care for veterans is at the very top of his list of priorities. Within a week, Filner, who is chairman of the House Veterans Affairs Committee, has demonstrated his advocacy and response to Legion concerns by introducing legislation long championed by the Legion that would materially aid Medicare-eligible vets.
Jumping elements in primates may have important consequences for studies of human genetic diseases
The density of transposable (jumping) elements between sex chromosomes in primates may have important consequences for the studies of human genetic diseases, say Penn State University researchers.
Face masks protect from COVID-19 and other respiratory illnesses
Now a new study published on the preprint server medRxiv in August 2020, therefore, presents the results of a meta-analysis that takes account of the lack of compliance with mask-wearing in RCTs, as well as the lag between the event and the measurable effects.
Boehringer Ingelheim's VERxVE study of nevirapine meets primary endpoint
New data were presented today at the 18th International AIDS Conference from the VERxVE study that show an investigational, once-daily extended-release (400 mg QD) formulation of nevirapine was non-inferior to twice-daily immediate release Viramune® (nevirapine) tablets (200 mg BID), both in combination with Truvada® (tenofovir and emtricitabine) tablets in treatment-naive HIV-1 infected patients through 48 weeks.
› Verified 2 days ago